Regeneron Pharmaceuticals Inc. buy Cantor Fitzgerald
Start price
29.10.25
/
50%
€558.60
Target price
29.10.26
€635.29
Performance (%)
15.05%
Price
26.01.26
€641.80
Summary
This prediction is currently active. The prediction currently has a performance of 15.05%. A total of €0.88 was paid as dividends for this prediction. This prediction currently runs until 29.10.26. The prediction end date can be changed by Cantor_Fitzgerald at any time. Cantor_Fitzgerald has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 3.683% | 3.683% |
| iShares Core DAX® | -0.121% | 2.507% |
| iShares Nasdaq 100 | 0.081% | -0.241% |
| iShares Nikkei 225® | -1.748% | 4.105% |
| iShares S&P 500 | -0.961% | -0.143% |
Comments by Cantor_Fitzgerald for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Cantor Fitzgerald from $678.00 to $740.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat